Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144793 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA4TDO2ELOVL1HCRTR2 | |
| SCHEMBL609606 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA4TDO2ELOVL1HCRTR2 | |
| SCHEMBL608698 | 0.84 | HPGD (0.36) | — | |
| SCHEMBL9895397 | 0.78 | LNPEP (0.34) | TDO2HCRTR2 | |
| SCHEMBL608679 | 0.71 | CHRNB2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL10121582 | 0.70 | HPGD (0.38) | CHRNB2CHRNA4HCRTR2HCRTR1 | |
| SCHEMBL29104585 | 0.68 | HRH3 (0.37) | ELOVL1 | |
| SCHEMBL19241779 | 0.65 | HCRTR2 (0.40) | HCRTR2HCRTR1 | |
| SCHEMBL15140101 | 0.65 | KDM4E (0.47) | TDO2ELOVL1GRM5 | |
| SCHEMBL16906756 | 0.65 | ELOVL1 (0.42) | TDO2ELOVL1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010122151-A1 | 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CHRNB2 120/4885CHRNA4 69/4885TDO2 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.